Amgen Inc. (NASDAQ:AMGN) Shares Sold by Highlander Capital Management LLC

Highlander Capital Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 0.4% in the first quarter, HoldingsChannel.com reports. The fund owned 22,940 shares of the medical research company’s stock after selling 100 shares during the quarter. Amgen comprises about 2.6% of Highlander Capital Management LLC’s portfolio, making the stock its 6th largest holding. Highlander Capital Management LLC’s holdings in Amgen were worth $5,547,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. AIA Group Ltd raised its holdings in Amgen by 40.4% in the 1st quarter. AIA Group Ltd now owns 2,938 shares of the medical research company’s stock worth $710,000 after purchasing an additional 845 shares during the period. Dixon Hughes Goodman Wealth Advisors LLC raised its holdings in Amgen by 905.2% in the 1st quarter. Dixon Hughes Goodman Wealth Advisors LLC now owns 1,156 shares of the medical research company’s stock worth $280,000 after purchasing an additional 1,041 shares during the period. IndexIQ Advisors LLC raised its holdings in Amgen by 2.3% in the 1st quarter. IndexIQ Advisors LLC now owns 10,095 shares of the medical research company’s stock worth $2,441,000 after purchasing an additional 225 shares during the period. Lindbrook Capital LLC raised its holdings in Amgen by 16.7% in the 1st quarter. Lindbrook Capital LLC now owns 2,358 shares of the medical research company’s stock worth $570,000 after purchasing an additional 337 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in Amgen by 9.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 13,077 shares of the medical research company’s stock worth $3,162,000 after purchasing an additional 1,136 shares during the period. Institutional investors and hedge funds own 79.01% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the sale, the executive vice president now directly owns 37,333 shares in the company, valued at $9,027,492.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $250.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 5,501 shares of the company’s stock, valued at $1,375,250. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $241.81, for a total value of $3,264,435.00. Following the transaction, the executive vice president now directly owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The disclosure for this sale can be found here. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on AMGN. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, May 16th. Mizuho boosted their price objective on Amgen from $202.00 to $208.00 in a research note on Tuesday, May 10th. Morgan Stanley boosted their price objective on Amgen from $239.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Friday, July 15th. TheStreet lowered Amgen from a “b+” rating to a “c+” rating in a research note on Wednesday, April 27th. Finally, Barclays boosted their price objective on Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $250.00.

Amgen Trading Down 0.3 %

Shares of Amgen stock opened at $246.25 on Friday. Amgen Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $258.45. The stock has a 50 day moving average of $245.14 and a 200 day moving average of $239.83. The firm has a market capitalization of $131.55 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 2.04 and a beta of 0.56. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44.

Amgen (NASDAQ:AMGNGet Rating) last announced its earnings results on Thursday, August 4th. The medical research company reported $4.65 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.25. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.53 billion. Amgen had a return on equity of 188.78% and a net margin of 24.92%. Amgen’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the business posted $4.38 EPS. As a group, research analysts predict that Amgen Inc. will post 17.38 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th will be paid a dividend of $1.94 per share. The ex-dividend date is Wednesday, August 17th. This represents a $7.76 dividend on an annualized basis and a yield of 3.15%. Amgen’s dividend payout ratio (DPR) is presently 65.76%.

Amgen Company Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.